JAMA Neurology Publishes Results from Positive Phase 3 Trial of EPIDIOLEX® (cannabidiol) oral solution in Children with Seizures Associated with Dravet Syndrome

NEXT STORY
Orion Corporation: Transfer of 94,317 own B shares on 2 March 2020
PREV STORY
Athenex’s Partner Almirall Announces EMA Acceptance for Filing of Marketing Authorization Application (MAA) for Tirbanibulin Ointment in Actinic Keratosis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Indi Molecular Appoints Stephen Worsley Senior VP Business Development

CULVER CITY, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Indi Molecular, an emerging life ...

author_avatar
NASDAQ Market News

Advaxis Announces First Patient Dosed in Phase 2 Trial Evaluating AXAL in Anal Cancer

FAWCETT study named to honor Farrah Fawcett, who passed away from HPV-associated anal cancer ...

author_avatar
NASDAQ Market News

Surgical Care Affiliates Partners With The Surgery Center at Doral

DEERFIELD, Ill., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Surgical Care Affiliates, Inc. (NASDAQ:SCAI) (“SCA”), ...

author_avatar
NASDAQ Market News